Navigation Links
Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
Date:1/31/2008

SEATTLE, Jan. 31 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of Daniel H. Petree and George R. Painter, Ph.D. to the Company's board of directors.

Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life science companies. Prior to forming P2 Partners, Mr. Petree held various executive management positions in the life sciences industry, including President and Chief Operating Officer of Axys Pharmaceuticals and Vice President of Business Development at TSI Corporation. He also served as Vice President in the Health Care Group at the investment bank Montgomery Securities. Mr. Petree currently serves as Director for Cypress BioSciences.

Dr. Painter is president and chief executive officer of Chimerix, a biotechnology company developing orally available antiviral therapeutics. Prior to that, he served as Executive Vice President, Research and Development, at Triangle Pharmaceuticals where he was a member of the founding management team. Dr. Painter has also held positions at Burroughs Wellcome Co., and Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-five patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more
'/>"/>

SOURCE Koronis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Access Pharmaceuticals Announces $2.7 Million New Equity
4. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
5. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
6. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
7. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...Cardiac now provides services to three out of top ... Rochester, NY (PRWEB) December 1, ...er in advanced cardiac core lab services and QT an...ical company has selected iCardiac as a preferred ...ovide Highly Automated QT(sm) and Dynamic QT beat-...
(Date:11/30/2009)... PRUSSIA, Pa., Nov. 30 Cadient In... in interactive marketing services and solutions ...aunch of its HATCH Consulting services group...trategic experts across a range of emerging areas ...ting team is committed to guiding companies and br...
(Date:11/30/2009)... November 30 Biopharmaceutical com...patients have been enrolled in its,multinational r...y is,designed to show reduction in transplant rela...logeneic stem cell transplantation with a mismatch...s eligible for an allogeneic,stem cell transplanta...
(Date:11/30/2009)...DS, a leader in providing smart and efficient soft...a Pathology®, evolutionizing work-from-home hi...ndard’ software used by 8 of the Top 10 Phar...;cost per slide’ basis. , ...09 -- PDS has announced another evolution in the h...
Breaking Biology Technology:Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3
... Calif., Dec. 12 Codexis, Inc., a leading,develop...day announced two,new directors have been named to...rd are Bill Rothwell, Ph.D., Vice President of Inn...utions, a unit of Royal Dutch Shell,plc and Dennis...leading,open source database company., "Our new d...
...lif., Dec. 12 Odyssey Thera, Inc.,announced today...e granted,U.S. Patent No. 7,306,914, entitled "Pro...e animals: applications to drug efficacy, ADME, ca...ene therapy." This is the,twelfth patent issued fo...bes a method for detecting protein-protein,interac...
...hase I Programme With Oral Iclaprim, "Rolling" NDA...mission of First Modules due Befor...2 Arpida Ltd,(SWX: ARPN) announced today the enro...e II clinical study with intravenous iclaprim in t.../ ventilator-associated pneumonia,(VAP) / healthca...
Other Biology Technology:Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5
(Date:12/1/2009)...io State University cancer researchers have develo...-tumor cells and blocks the growth of new tumor bl... designed to kill cancer cells oncolytic viruses ...tumors if they also carry a gene for a protein tha...lled vasculostatin, is normally produced in the br...
(Date:12/1/2009)... Hit-and-run attacks by sharks can be solved with ...e unique chomp they put on their victims, accordin...expert. , In a method analogous to analyzing hum...ns by precisely comparing shark bites to the jaws ...urgess, director of the International Shark Attack...
(Date:12/1/2009)...it was an ,abominable mystery, and it is a questio... day: when did flowering plants evolve and how did...a study in Ecology Letters reveals the evolution...ining a major competitive advantage over rival spe...ce. , The study, by Dr Tim Brodribb and Dr Tayl...
Breaking Biology News(10 mins):Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3How did flowering plants evolve to dominate Earth? 2Boot Camp for New Dads Now Working with Renowned Katherine Stone Educating Fathers about Postpartum Depression 53314 1Boot Camp for New Dads Now Working with Renowned Katherine Stone Educating Fathers about Postpartum Depression 53314 2Boot Camp for New Dads Now Working with Renowned Katherine Stone Educating Fathers about Postpartum Depression 53314 3Boot Camp for New Dads Now Working with Renowned Katherine Stone Educating Fathers about Postpartum Depression 53314 4March of Dimes Celebrates 50th Anniversary of Genetics Short Course 53310 1March of Dimes Celebrates 50th Anniversary of Genetics Short Course 53310 2Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 1Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 2Free Compirion Webinar Promotes Nurse Rounding to Improve Patient Safety 53306 3
... percent of deaths from SIDS (sudden infant death ...fects in one gene and half of those deaths result ...infant,s risk of developing an abnormal heart rhyt...h team based at the University of Chicago reports ...cal Investigation. , Children with two copies of ...
... at Northwestern University have determined the mo...uenza virus 5 fusion (F) protein. The parainfluenz...viruses) that causes everything from pneumonia, cr...responsible for many hospitalizations and deaths e...the journal Nature. , Details of the protein,s str...
... have determined the detailed structure of an esse... contributor to the vast majority of human cancers...has led to a better understanding of how it acts t...sign broadly effective cancer drugs. , Until now, ...the enzyme has hindered progress in developing age...
Other Biology News:Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3Scientists identify molecular structure of key viral protein 2Scientists identify molecular structure of key viral protein 3Scientists identify molecular structure of key viral protein 4Report lists top 20 most-vulnerable African carnivores 2Report lists top 20 most-vulnerable African carnivores 3Report lists top 20 most-vulnerable African carnivores 4
Microtiter Wells from Bethyl Laboratories
Human Atherosclerosis Antibody Array I Kit, ChemiArray, 20 cytokines per membrane from CHEMICON
Complement, Guinea Pig Serum from Calbiochem
Zymoclean Gel DNA Recovery Kit from Zymo Research
Biology Products: